Vabysmo

News

Vabysmo vaults into Roche’s top growth spot

The undisputed star of Roche’s pharma portfolio in the first quarter of this year is eye disease therapy Vabysmo, heading for blockbuster territory after posting sales of

News

Trials cue up new use for Roche's eye disease drug Vabysmo

Roche is on course for a third indication for its fast-growing ophthalmic disease therapy Vabysmo, after a pair of phase 3 trials showed it was effective at improving eyes

News

Roche Q3 results show steep fall-off in COVID product sales

Roche's third-quarter results have revealed a clear sign that the bumper sales boosting companies that have provided products to diagnose, treat or prevent COVID-19 since the start of the p

News

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

A higher dose of Regeneron and Bayer's Eylea given every three or four months has shown efficacy in a pair of clinical trials, in a big boost for the multibillion-dollar product.

News

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche has been trumpeting the rapid uptake of its new eye disease drug Vabysmo as it takes on Regeneron and Bayer's mighty Eylea in the US – and could soon start making inroads against its

News

Roche grabs FDA okay for would-be blockbuster eye drug faric...

The FDA has approved Roche's much-anticipated faricimab for two major causes of blindness, setting up a market clash with Bayer and Regeneron's market leading drug Eylea.

Vabysmo vaults into Roche’s top growth spot

Trials cue up new use for Roche's eye disease drug Vabysmo

Roche Q3 results show steep fall-off in COVID product sales

Eylea data gives Regeneron/Bayer a lift in ophthalmic diseas...

Roche's fast-growing eye drug Vabysmo set for EU approval

Roche grabs FDA okay for would-be blockbuster eye drug faric...

Alzheimer's patients 'not changing brain health behaviours'

Discover a new era of healthcare panel engagement: Grounded ...

Vabysmo

Editor's Picks